Notable increases were observed in the prescription of nirmatrelvir/ritonavir, which rose from 25.5% to 38.3% in case 1 (immunosuppressed, vaccinated, and no CYP3A-metabolized drugs), 31.3% to 49.4% in case 3 (immunosuppressed, unvaccinated, and no CYP3A-metabolized drugs), 12.8% to 22.3% in case 5 (obesity, vaccinated, and no CYP3A-metabolized drugs), and 15.1% to 33.7% in case 7 (obesity, unvaccinated, and no CYP3A-metabolized drugs). The gene discussed is CYP3A4; the disease is obesity disorder.